Adrian Tyndall, M.D. MPH, FACEP is joining Axogen, Inc.’s Board of Directors and Mark Gold, M.D., founding director, is retiring effective December 13, 2022.
Dr. Tyndall Joins AxoGen BOD as Founding Director Dr. Gold Retires
2 min read Premium comments
#axogen#adriantyndall#markgold
AxoGen develops products and methods of processing allograft tissues for use in peripheral nerve regeneration and repair. Dr. Tyndall will serve on the Quality, Compliance, and Portfolio Management Committee.
Dr. Tyndall currently serves as the executive vice president for health affairs and dean of Morehouse School of Medicine. He is also the president of the Society for Academic Emergency Medicine Foundation and was also recently elected to serve on the administrative board of the Council of Deans of the Association of American Medical Colleges (AAMC). He has both researched and published on traumatic and ischemic brain injuries.
Prior to joining Morehouse School of Medicine, Dr. Tyndall spent over 13 years at the University of Florida College of Medicine and University of Florida Health as professor, emergency medicine department chair, trauma researcher, interim dean, and associate vice president.
A graduate of the University of Maryland School of Medicine, Dr. Tyndall completed his residency in emergency medicine at the University of Maryland Medical Center and the R Adams Cowley Shock Trauma Center. Per the press release, he is “board-certified in emergency medicine by the American Board of Emergency Medicine and an American College of Emergency Physicians Fellow.” He completed his master’s degree in health services management and health policy at Columbia University and his bachelor’s degree in chemistry at The George Washington University.
AxoGen Chairman, CEO, and President Karen Zaderej commented, “We are delighted to welcome Dr. Tyndall to the board. His wealth of experience in emergency care, trauma research, and academia will be of tremendous value in supporting our mission to restore nerve function and quality of life to patients with peripheral nerve injuries.”
Dr. Gold has served on AxoGen Corporation’s Board of Directors since July 2007. A retired professor, Dr. Gold continues to serve as a consultant and senior advisor on medical devices, pharmaceuticals, and health care service.
Zaderej commented, “On behalf of the board of directors, I want to thank Dr. Gold for his dedication and innumerable contributions to AxoGen. He has been instrumental in guiding our organization since the beginning and we wish him all the best in his retirement.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.